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Summary Cells of osteogenic sarcoma line 791T were treated in vitro with a selectively cytotoxic
methotrexate-human serum albumin-monoclonal antibody conjugate at concentrations which were toxic but
allowed the "escape" of a small number of tumour cell colonies (<0.3% compared with controls). These
colonies were propagated as clones in order to test their expression of the monoclonal antibody (791T/36)-
defined antigen and their resistance to methotrexate (MTX) by comparison with parental cells. Most of the
conjugate-treated clones were incapable of prolonged growth and died out, in contrast to untreated 791T
clones which virtually always grow progressively. Only four treated clones grew at rates comparable with the
parental line. Flow cytofluorometric analysis indicated that the surviving clones expressed normal or
enhanced amounts of 791T/36-defined antigen and clonogenic assays demonstrated that they were sensitive to
cytotoxicity by MTX. As could be predicted from these results, further exposure to the conjugate inhibited
growth of the clones at doses comparable with those active against parental 791T cells. It is concluded that
tumour cell clones emerging after exposure to a toxic concentration of a drug-antibody conjugate are not
necessarily modified resistant clones, but may have severely impaired long-term growth potential or be
susceptible to further contact with the same conjugate.
The use of antibodies as a means of targeting
therapeutic agents has undergone renewed emphasis
in recent times following the introduction of
hybridoma techniques for preparing monoclonal
antibodies (K6hler & Milstein, 1975). Several
groups have shown that anti-tumour antibodies can
be used to direct toxins or therapeutic drugs to
appropriate tumour cells and thereby achieve
increased cytotoxicity (Ghose & Blair, 1978; Thorpe
& Ross, 1982). We have previously reported the
selective action in vitro of conjugates of vindesine
or methotrexate (MTX) with a monoclonal
antibody to a human osteogenic sarcoma cell line,
against target cells which express the relevant
antigen (Embleton et al., 1983; Garnett et al.,
1983).
The successful use of such conjugates depends on
a number of transport-related factors such as the
ability of the conjugate to localise and persist at the
tumour site, and its intratumour and intracellular
penetration. The behaviour of the tumour cells
themselves in response to the conjugate will also
determine its overall therapeutic efficacy. In
conventional cancer chemotherapy the development
of resistance to drugs, such as MTX, is a common
problem (Harrap et al., 1971) and this is equally
possible in the case of drug-antibody conjugates. In
addition, there is the possibility that tumour cells
might lose antigen expression, either by selection of
non-antigenic clones or by antibody-induced
modulation, and consequently fail to bind sufficient
conjugate to achieve cytotoxicity.
It is highly unlikely that a single dose of a drug-
antibody conjugate would deplete the host of all
tumour cells in in vivo therapy, mainly because of
limited access to the whole cell population. It is
therefore likely that some cells will survive the
initial treatment, and it is of interest to determine
to what extent they may be modified in terms of
factors influencing their subsequent susceptibility.
We have investigated this problem using an in vitro
model in which cells of a human osteogenic
sarcoma line (791T) were treated with a conjugate
of methotrexate (MTX) linked to an anti-osteogenic
sarcoma antibody (79IT/36) by a human serum
albumin bridge (Garnett et al., 1983).
Materials and methods
Tumour cells
The human osteogenic sarcoma line HS-791T
(791T) was maintained as a monolayer cell line in
90mm plastic culture dishes (Sterilin, Teddington,
U.K.) in Eagles Minimum Essential Medium
supplemented with 10% newborn calf serum
(growth medium), and routinely passaged by
harvesting with a mixture of 0.25% trypsin and
0.5% EDTA in Hanks' balanced salt solution
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(HBSS). Clones derived from this cell line were
grown and passaged in an identical manner.
Conjugate
The conjugate consisted of methotrexate linked via
human serum albumin to anti-osteogenic sarcoma
antibody 791T/36 (Embleton et al., 1981) as
previously described (Garnett et al., 1983). It will
be referred to as MXT-HSA-791T/36 conjugate.
Previous studies have established that it is cytotoxic
for 791T and other tumour cells expressing the
791T/36-defined antigen, but not for cells which do
not express the antigen (Garnett et al., 1983). It
was stored in PBS (pH7.2) at 4°C, under which
conditions it was stable for more than 12 months.
Isolation ofclones surviving treatment with conjugate
791T cells (103) were plated in 60mm culture dishes
in 4ml of growth medium, either untreated or
containing MTX-HSA-791T/36 conjugate at MTX
concentrations of 50ngml -1 or 100ngml-1. These
concentrations were chosen because they had
previously resulted in between 99% and 100%
inhibition of 791T colony growth (Garnett et al.,
1983). The dishes were incubated for 10 days at
37°C, and were examined microscopically for 791T
colonies. The few colonies observed in MTX-HSA-
791T/36 treated dishes were isolated in greased
glass cloning cylinders and trypsinised from the
dishes (Puck et al., 1956). The cells were seeded
into separate 16mm diameter wells of a 24-well
culture plate (Costar, Cambridge, Massachusetts,
U.S.A.) in normal growth medium. Cells which
continued to grow were expanded successively
through 35mm, 60mm and 90mm culture dishes
and were maintained as clones, designated
791T/MH7R clones. For comparative studies,
normal clones of 791T were isolated by limiting
dilution in microtiter plates (Sterilin, Teddington,
U.K.) and expanded in the same way as
791T/MH7R clones.
(Becton-Dickinson FACS IV). Mean fluorescence
intensity was recorded as the mean fluorescence
channel number on a linear scale, which is directly
proportional to intensity. The lowest antibody
concentration gave virtually background levels of
emission and the highest gave plateau readings, but
readings for the intermediate concentrations were
subjected to linear regression analysis in order to
calculate slopes. Because 791T cells exhibit a fairly
wide range of fluorescence with FITC-791T/36 in
different experiments, a "normal range" of slopes
was prepared using uncloned parental cells tested
on four different occasions and ten different normal
clones of 791T, under conditions identical to those
used for the 791T/MH7R clones. The antigenicity
of the 791T/MH7R clones was then judged by
comparing their slopes with the normal range.
Colony inhibition assay
Toxicity of free MTX (Lederle Laboratories,
Gosport, U.K.) or MTX-HSA-791T/36 for 791T
cells and 791T/MH7R clones was tested by a
colony inhibition assay. Two hundred cells were
plated in 1 ml of growth medium in 35mm culture
dishes and incubated for 4h at 37°C to allow
attachment. Using quadruplicate dishes 1 ml of
growth medium was added, containing various
dilutions of MTX or conjugate (at equivalent MTX
concentrations) as appropriate. In each case
controls were included which contained added
growth medium only. The dishes were incubated 5-
6 days at 37°C. They were then rinsed with 0.9%
w/vNaCl and the cell colonies were fixed with
methanol and stained with 0.1% aqueous crystal
violet solution. Colonies were counted under x40
stereoscopic magnification and the results were
expressed, for each cell line, as percentage colony
growth relative to that in controls, i.e.
Mean no. of colonies in MTX or conjugate
Mean no. of colonies in medium controls 100
Assayfor antigenicity
The expression of monoclonal antibody 791T/36-
defined antigen on 791T/MH7R clones was
analysed by flow cytofluorometry using affinity-
purified 791T/36 conjugated to fluorescein
isothiocyanate (FITC) (Price et al., 1983). The
antigen recognised by this antibody is a membrane-
associated monomeric glycoprotein of apparent
molecular weight 72,000 (Price et al., 1983). Cells
(2 x 10) were incubated for 30min at 4°C with ten-
fold dilutions of FITC-791T/36 in 1 ml of PBS or
HBSS, ranging from 20jugml- 1 to 2ngml-1
antibody protein. They were then examined for
fluorescence in a fluorescence-activated cell sorter
Percent colony growth was plotted against
concentration of drug or conjugate to estimate ICSO
values (concentration resulting in 50% inhibition of
colonies). Differences between 791T/MH7R clones
and parental 791T cells were assessed for statistical
significance by Student's t test.
Growth ofclones in immune-deprived mice
Female mice (Bantin and Kingman, Hull, U.K.)
were thymectomised at 3-4 weeks of age and up to
20 weeks later were given cytosine arabinoside
(200mgkg-1). After two days the mice were
subjected to 9Gy whole-body y-irradiation and
were used as recipients of xenografts within 2CELLS ESCAPING A CYTOTOXIC DRUG-ANTIBODY CONJUGATE 561
weeks. Inocula of 106 cultured 791T or
791T/MH7R cells were injected subcutaneously in
the right flank and the mice were maintained for 2
months to observe the growth ofxenografts.
Results
Isolation of clones following MTX-HSA-79JT/36
treatment
Treatment with MTX-HSA-791T/36 conjugate at
doses of 50ngml-1 and lOOngml-1 markedly
inhibited growth of 791T cells as reported
previously (Garnett et al., 1983). Table I indicates
the plating efficiency of the cells in control medium
and in treated dishes, equating to inhibitions of
99.7% and 99.9% at 50 and lOOngml-P
respectively, relative to the controls. The surviving
colonies each contained more than 50 cells 10 days
after plating. Fifteen colonies were obtained from
23 treated dishes, and all were isolated and
subcultured separately for expansion through
progressively larger culture vessels. Of these
cultures, 11 became senescent and died out at an
early stage. Only 4 of the 15 conjugate-treated
clones progressed to become permanent cell lines.
This is in marked contrast to normal clones of
791T cells which continue to proliferate indefinitely
in virtually 100% of cases, whether isolated by
cloning cylinders or by limiting dilution in
Microtiter plates. The four treated subclones thus
derived were designated 791T/MH7R/4,
791T/MH7R/5, 791T/MH7R/12 and
79lT/MH7R/14.
Antigenicity
Cells of the subclones and the uncloned parental
791T line were incubated in FITC-labelled antibody
791T/36 at various dilutions and assayed for
fluorescence intensity by flow cytofluorometry
(Price et al., 1983). Mean fluorescence intensity
(mean channel number of the fluorescence profile)
was plotted against antibody concentration and
linear regression slopes were calculated. The mean
values for two separate experiments are shown in
table II. These data show a wide variation in
fluorescence intensity, with two of the subclones
showing greater fluorescence than the parental cells
and two showing less. This variation must be
considered in the light of natural fluctuation in
791T/36-defined antigen density of 791T cells,
which is readily observed in repeated tests using
identical conditions. The reasons for this
fluctuation are not clear, but factors such as the
age and density of the culture, serum concentration
and rate of growth are known to affect antigen
density. A "normal range" of slopes was therefore
established for 791T cells using conditions identical
to those used in the analysis of 791T/MH7R
subclones. Figure 1 shows the slopes obtained with
10 normal clones of 791T, and four independent
tests with uncloned 791T cells. It is apparent that
the normal clones fell within the range of
fluctuation characteristic of uncloned 791T.
Moreover, FACS fluorescence profiles were similar
in shape for all of the cell lines, indicating a similar
scatter about their mean values (data not shown).
The normal range corresponds to a mean density of
106 antibody-binding sites per cell (Price et al.,
1983).
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Figure 1 Monoclonal antibody 791T/36-defined antigen
on normal clones of osteogenic sarcoma 791T and
uncloned parental cells, assayed by cytofluorometry.
Linear regression slopes were calculated by plotting mean
fluorescence intensity (mean FACS channel number)
against concentration of FITC-labelled antibody 791T/36.
The extremes of the slopes obtained form the normal
range illustrated in Figure 2.
Table I Isolation of MTX-HSA-791T/36 "resistant" clones of
osteogenic sarcoma 791T
Dose ofconjugate Plating efficiency No. ofcolonies isolated
(ngml-1 MTX) of791T cells (%) No. ofdishes treated
0 38.8
50 0.11 11/10
100 0.03 4/13562 M.J. EMBLETON et al.
Table II Antigenicity of 791T osteogenic sarcoma cells and 791T/MH7R clones
by flow cytofluorometric analysis using fluorescein-conjugated 791T/36
monoclonal antibody
Cell Antibody conCn.a Mean channel no. Correlationb
line (ngml 1) (linear scale) Slopeb coefficient
791T 20 32
200 228 0.2925 0.9778
2000 675
79lT/MH7R/4 20 56
200 415 0.4930 0.9700
2000 1148
791T/MH7R/5 20 40
200 264 0.2107 0.9270
2000 537
791T/MH7R/12 20 68
200 591 1.2964 0.9948
2000 2759
791T/MH7R/14 20 40
200 244 0.1763 0.9128
2000 463
aCells (2 x 10') were incubated with FITC-791T/36 in 1 ml of PBS or HBSS for
30min at 4°C.
'Slopes and correlation coefficients were calculated by linear regression analysis.
Comparison of the slopes of 791T/MH7R clones
with this normal range showed that two lines
(791T/MH7R/5 and 791T/MH7R/14) fell within the
normal range but the other two (791T/MH7R/4
and 791T/MH7R/12) exhibited heightened
fluorescence intensity indicative of increased
antigenicity (Figure 2). By comparison with the
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Figure 2 Antigenicity of 791T/MH7R clones by
comparison with the normal range for 791T osteogenic
sarcoma cells. The normal range is indicated by the
stippled area, and mean slopes for 791T/MH7R clones are
indicated by the unbroken lines.
normal antigen density 791T/MH7R/12 can be
estimated to express approximately 6 x 106 antigenic
sites per cell. None of the 791T/MH7R clones
showed reduced antigenicity.
Colony inhibition tests
Colony inhibition tests were performed initially to
determine whether 791T/MH7R clones were
resistant to MTX compared with 791T parental
cells. Plated cells were exposed continuously to
various concentrations of MTX and after 5 days
the colonies were enumerated and compared with
numbers in untreated controls (Table III). MTX
completely inhibited the growth of 791T cells at
100ngmlP-, and the IC50 was 9ngml-1 in repeated
experiments. Three of the four 791T/MH7R clones
showed almost identical sensitivity to MTX, but
791T/MH7R/5 was more resistant in the 10-
30ngml-1 range, resulting in an IC50 of 17ngml-1.
Considering the persistence of 791T/36-defined
antigen and the essentially normal sensitivity to
MTX, it could be predicted that 791T/MH7R
clones should be susceptible to a further exposure
to MTX-HSA-791T/36 conjugate. This was tested
(Table IV) and in all cases the clones were inhibited
by the conjugate. (Clone 791T/MH7R/4 appeared
slightly more sensitive to low doses, and clones
791T/MH7R/12 and 791T/MH7R/14 were slightly
more resistant to high doses than the parental 791TCELLS ESCAPING A CYTOTOXIC DRUG-ANTIBODY CONJUGATE 563
Table III Inhibition of colony formation by osteogenic sarcoma 791T and 791T/MH7R clones
in medium containing methotrexate (MTX)
Colonyformation (% ofcontrol+se)a by cell line:
Dose of
MTX (ngml-') 791T 791T/MH7R/4 791T/MH7R/5 791T/MH7R/12 791T/MH7R/14
1 100+3 94+5 96+3 98+3 74+9
3 94+6 96+5 95+2 88+3 68+9
10 46+4 43+2 84+5**b 43+2 50+5
30 0.2+0.1 0.5+0.3 10+ 1*** 0.5+0.5 0.5+0.5
100 0 0 0.2+0.2 0 0.2+0.1
300 0 0 0 0 0
1000 0 0 0 0 0
IC50c
(ngmP'): 9 9 17 8 10
a%Colony formation for each cell line at various concentrations of MTX was calculated with
respect to the mean number of colonies in the medium control for the respective line; colony
formation in the absence of drug thus equals 100% in each case. Absolute plating efficiencies in
controls varied between 30% and 93% in the experiments shown in Tables III and IV.
bValues indicated by asterisks differed significantly from values for 791T parental cells at the
same dose of MTX, by Student's t test; **P<0.01, ***P<0.001. Unmarked values did not differ
significantly from those obtained with 791T.
'IC50=Concentration of MTX producing 50% inhibition of colony formation.
Table IV Inhibition of colony formation by osteogenic sarcoma 791T and 791T/MH7R
clones in medium containing methotrexate-HSA-791T/36 conjugate.
Dose of Colonyformation (% ofcontrol± se)a by cell line:
conjugate
(ngml-' MTX) 791T 791T/MH7R/4 791T/MH7R/5 791T/MH7R/12 791T/MH7R/14
1 73+4 60+3*b 72+3 70+8 89+3*
3 25+3 16+1* 25+4 24+3 49+3**
10 7+2 6+1 6+1 16+3* 22+3**
30 2+1 0 3+1 8+1*** 16+2***
100 0 0 0.4+0.3 0.4+0.4 4+ 1*
300 0 0 0 0 0
1000 0 0 0 0 0
IC50c
(ngml-1 MTX): 2 1.5 2 2 3
a,bccSee footnotes to Table III *P<0.05, **P<0.01, ***P<0.001.
line. However, although statistically significant,
these differences were small and the IC50 values
were closely similar for all the cell lines.
Growth in athymic mice
The growth of all four 791T/MH7R clones in
thymectomised and irradiated mice was tested in
comparison with 791T, which grows reproducibly
as a xenograft from a subcutaneous inoculum of
106 cells. All four clones grew tumours at rates
comparable with 791T when administered at the
same cell dose.
Discussion
One of the potential problems envisaged in the use
of drug-antibody conjugates in therapy of human
tumours is the emergence of resistant clones. This
might be more likely to occur with conjugates than
with conventional cytotoxic drugs, owing to the
additional possibility of antigenic modulation or the
existence of clones deficient in the antigen
recognised by the antibody moiety of the conjugate.
It has been shown previously by competition assays
that antibody binding to target cells is an essential564 M.J. EMBLETON et al.
requirement for cytotoxicity by MTX-HSA-791T/36
conjugate against osteogenic sarcoma 791T
(Garnett et al., 1983). These studies had also
indicated that a small number of 791T clones might
survive an initial exposure to the conjugate, and it
was of interest to examine these for growth
properties, antigenicity and drug susceptibility. It is
apparent from the present investigation that clones
which initially survive conjugate treatment fall into
two categories, the majority subsequently failing to
proliferate indefinitely and the minority growing at
a similar rate to parental cells both in vivo and in
vitro. Only the latter clones became available in
numbers great enough for more detailed analysis.
The proliferating conjugate-treated
(791T/MH7R) clones showed no loss of 791T/36-
defined antigen as detected by flow
cytofluorometry, based on the range of antigenicity
of uncloned 791T or normal 791T clones. On the
contrary, two 791T/MH7R clones showed enhanced
antigenicity for which there was no obvious
explanation nor any correlation with other
parameters. For example, 791T/MH7R/12, with an
antigen density 6 times higher than the normal
mean, showed no increased susceptibility to
conjugate. Flow cytofluorometric studies have
indicated that the 791T/36-defined antigen is
present on all 791T cells, either cultured or
obtained by dissociation of xenografts (Price et al.,
1983; R.A. Robins, unpublished findings) but it
could be postulated that non-antigenic clones might
exist below the limits of detection. However, this is
evidently not the explanation for escape from the
MTX-HSA-791T/36 conjugate. The relative
antigenic homogeneity characteristic of 791T is a
feature not likely to be shared by hwnan tumours
experienced clinically, but this problem might be
overcome by using "cocktails" of antibodies with
different specificities, as is the current practice in
removal of neoplastic cells from bone marrow
aspirates (Treleaven et al., 1984). The emergence of
"non-antigenic" clones might thus also be a rare
event in clinical practice.
The 791T/MH7R clones were sensitive to MTX
in the form of free drug, and subsequent tests
confirmed the prediction that they would be as
sensitive to the cytotoxic effect of MTX-HSA-
791T/36 conjugate as the untreated 791T parental
line. There were minor differences in colony
formation at particular concentrations of conjugate,
but the IC50 values for parental cells and clones fell
in the narrow range of 1.5 to 3.0ngm1-1 expressed
in terms of MTX content. Extrapolated to the in
vivo situation, these extremes are unlikely to be of
practical significance in therapy. It is possible that
these clones arose from cells which temporarily
became drug-insensitive during the initial exposure
but regained their susceptibility during subsequent
clonal expansion, or that the threshold of
effectiveness of MTX was not reached in the initial
exposure.
The overall conclusion from these experiments is
that cells escaping the effects of a cytotoxic drug-
monoclonal antibody conjugate do not necessarily
constitute truly resistant clones, but may be either
incapable of further progressive growth (i.e. only
short-term survivors) or long-term survivors
susceptible to a further treatment with the same
conjugate. This supports the design of protocols for
in vivo therapy employing multiple doses of
conjugate spread over an extended time period.
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